Purinergic Signalling and Neurological Diseases: An Update. [PDF]
CNS and Neurological Disorders - Drug Targets, 2017 Purinergic signalling, i.e. ATP as an extracellular signalling molecule and cotransmitter in both peripheral and central neurons, is involved in the physiology of neurotransmission and neuromodulation.
G. Burnstock
semanticscholar +5 more sources
Neonatal Seizures and Purinergic Signalling. [PDF]
Int J Mol Sci, 2020 Neonatal seizures are one of the most common comorbidities of neonatal encephalopathy, with seizures aggravating acute injury and clinical outcomes. Current treatment can control early life seizures; however, a high level of pharmacoresistance remains ...
Menéndez Méndez A, Smith J, Engel T.
europepmc +5 more sources
Purinergic Signalling and Inflammation-Related Diseases [PDF]
Cells, 2022 While acute inflammation is widely accepted as an important response mechanism of cells against tissue injury, sustained inflammatory processes are increasingly recognized as one of the main contributors to numerous diseases, including central-nervous ...
Tobias Engel +2 more
doaj +2 more sources
Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies.
Drug Resistance Updates, 2023 Purinergic signalling, consisting of extracellular purines and purinergic receptors, modulates cell proliferation, invasion and immunological reaction during cancer progression.
Wenhui Jia +9 more
semanticscholar +3 more sources
Purinergic signalling in the cardiovascular system-a tribute to Geoffrey Burnstock. [PDF]
Purinergic Signal, 2021 Geoffrey Burnstock made groundbreaking discoveries on the physiological roles of purinergic receptors and led on P2 purinergic receptor classification. His knowledge, vision and leadership inspired and influenced the international scientific community. I
Ralevic V.
europepmc +2 more sources
Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities. [PDF]
JHEP Rep, 2020 Summary Extracellular nucleotides, including ATP, are essential regulators of liver function and serve as danger signals that trigger inflammation upon injury.
Wang P, Jia J, Zhang D.
europepmc +2 more sources
Purinergic signalling in neuroregeneration
Neural Regeneration Research, 2015 Purinergic signalling, adenosine 5′-triphosphate (ATP) as an extracellular signalling molecule, was proposed in 1972 (Burnstock, 1972). However, it was not generally accepted until the early 1990s when receptors for ATP and its breakdown product adenosine were cloned and characterised (Ralevic and Burnstock, 1998).
Geoffrey Burnstock
doaj +4 more sources
Purinergic signalling in bone [PDF]
Frontiers in Endocrinology, 2012 Purinergic signalling in bone was first proposed in the early 1990s with the observation that extracellular ATP could modulate events crucial to the normal functioning of bone cells.
Robin Mark Howard Rumney +3 more
doaj +5 more sources
Editorial: Purinergic signalling in the central nervous system and its pharmacological importance in neurological and psychiatric illnesses [PDF]
Frontiers in Pharmacology, 2023 Yong Tang +5 more
doaj +2 more sources
Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration. [PDF]
Neurochem Res, 2019 Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by progressive loss of dopaminergic neurons that results in characteristic motor and non-motor symptoms.
Tóth A +3 more
europepmc +2 more sources